These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35388509)

  • 21. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings.
    Donkoh ET; Dassah ET; Owusu-Dabo E
    BMC Womens Health; 2022 Jun; 22(1):234. PubMed ID: 35710373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.
    Hernandez BY; Ton T; Shvetsov YB; Goodman MT; Zhu X
    Clin Vaccine Immunol; 2012 Sep; 19(9):1348-52. PubMed ID: 22761294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.
    Toft L; Tolstrup M; Müller M; Sehr P; Bonde J; Storgaard M; Østergaard L; Søgaard OS
    Hum Vaccin Immunother; 2014; 10(5):1147-54. PubMed ID: 24553190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
    Dessy FJ; Giannini SL; Bougelet CA; Kemp TJ; David MP; Poncelet SM; Pinto LA; Wettendorff MA
    Hum Vaccin; 2008; 4(6):425-34. PubMed ID: 18948732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
    Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
    Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
    Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
    Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques.
    Wang Y; Liu Y; Liang S; Yin F; Zhang H; Liu Y
    Papillomavirus Res; 2020 Dec; 10():100209. PubMed ID: 33197649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries.
    Gohar A; Abdeltawab NF; Shehata N; Amin MA
    Papillomavirus Res; 2019 Dec; 8():100172. PubMed ID: 31185296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
    Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
    Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.
    Opalka D; Lachman CE; MacMullen SA; Jansen KU; Smith JF; Chirmule N; Esser MT
    Clin Diagn Lab Immunol; 2003 Jan; 10(1):108-15. PubMed ID: 12522048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.
    Kahn JA; Xu J; Kapogiannis BG; Sleasman JW
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):241-245. PubMed ID: 28291048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A time-resolved fluorescence immunoassay for rapid and precise automatic quality control of human papillomavirus type 68 VLPs in human papillomavirus vaccine.
    Li Z; Wu M; Chen Y; Li Y; Zhang Z; Zhai X; Cao Y; Li X; Yang Y; Wu Y; Lin G
    J Immunol Methods; 2023 Aug; 519():113518. PubMed ID: 37385433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
    Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
    J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.